RT Conference Proceedings
T1 Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations
A1 de Bono, J. S.
A1 Mateo, J.
A1 Fizazi, K.
A1 Saad, F.
A1 Shore, N.
A1 Sandhu, S.
A1 Chi, K. N.
A1 Sartor, O.
A1 Agarwal, N.
A1 Olmos, D.
A1 Thiery-Vuillemin, A.
A1 Twardowski, P.
A1 Roubaud, G.
A1 Ozguroglu, M.
A1 Kang, J.
A1 Burgents, J.
A1 Gresty, C.
A1 Corcoran, C.
A1 Adelman, C. A.
A1 Hussain, M.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-09-01
LK https://hdl.handle.net/10668/26987
UL https://hdl.handle.net/10668/26987
LA en
DS RISalud
RD Apr 10, 2025